Nuvectis Pharma (NVCT) Stock Forecast: StockMap's 2-Week Call

NVCT stock forecast: StockMap's model leans Underperform on Nuvectis Pharma for the two weeks after the Nov 19 close, toward NVCT trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 1 of 3 two-week windows on NVCT since Sep 29; by chance, a call on the same dates was right 47% of the time.

Nuvectis Pharma last closed at $19.84, -2.22% on the session.

Against the IVW growth benchmark the position is +0.11% over the forecast window.

Nuvectis Pharma's market cap is $682.26M as of November 19, 2026.

Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -27 (too close to call).

Where NVCT sits: sized by market cap, coloured by the day's move.

The read is built from 15 underlying insights — 6 bullish and 9 bearish.

Agreement across those insights is 60%.

21 daily calls for NVCT so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Nuvectis Pharma in the 9th percentile on return on equity, where 100 is best.

Nuvectis Pharma is classified under Health Care / Biotechnology.

StockMap tracks Nuvectis Pharma as the 148th largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.

On that composite Nuvectis Pharma ranks 213th of 394 in the group, against a group median of -0.27.

Other Health Care stocks

Research and education, not investment advice. The calls on this page come from StockMap's automated model, run on the close of November 19, 2026, and are the same for every reader. Calls are graded in public, misses included: how calls are graded, and the record. Who makes the calls and who pays for the site: Disclosures.

Nuvectis Pharma (NVCT) — StockMap 2-week forecast & tracked accuracy